SCHEMBL28021607

SCHEMBL28021607

COc1ccc(Cc2cc(Nc3cc(C)n[nH]3)nc(S(=O)(=O)c3ccc(NC(C)=O)cc3)n2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC2A1 P11166 1/20 0.44
▸ KDM4E B2RXH2 2/20 0.42
▸ TNIK Q9UKE5 1/20 0.40
▸ IDO1 P14902 1/20 0.39
▸ MAPT P10636 3/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ LMNA P02545 2/20 0.39
▸ GLA P06280 1/20 0.39
▸ ACHE P22303 1/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ GAA P10253 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ NAMPT P43490 1/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ CYP2D6 P10635 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28549342 0.86 ACHE (0.48) SLC2A1KDM4ETNIKIDO1MAPT
SCHEMBL28022078 0.79 PKM (0.44) KDM4EMAPTALDH1A1LMNAGAA
SCHEMBL28022048 0.79 AURKA (0.46) KDM4EMAPTALDH1A1CYP2C19
SCHEMBL28021626 0.77 ATM (0.46) MAPTALDH1A1MEN1KMT2A
SCHEMBL28557357 0.77 AURKB (0.49) KDM4ETNIKMAPTALDH1A1SMN1; SMN2
SCHEMBL28021678 0.76 ATM (0.45) KDM4EMAPTALDH1A1LMNAGLA
SCHEMBL28022063 0.75 SMN1; SMN2 (0.42) KDM4EMAPTALDH1A1LMNASMN1; SMN2
SCHEMBL28556178 0.75 AURKA (0.39) KDM4EMAPTALDH1A1SMN1; SMN2GAA
SCHEMBL28570362 0.75 RET (0.43) MAPTALDH1A1LMNAACHESMN1; SMN2
SCHEMBL28570313 0.75 KMT2A (0.37) KDM4EMAPTALDH1A1SMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104797267-A Method of treating tyrosine kinase inhibitor-resistant malignancies in patients with genetic polymorphism or AHI1 dysregulation or mutation using dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof DEL MAR PHARMACEUTICALS 2015-07-22 — — CN disclosed
Send feedback